2024/04/26 17:37:36 | |
---|---|
Price | |
11.70 EUR | |
Difference | -1.27% (-0.15) |
ISIN | BE0974363955 |
Symbol | 52U |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 202 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - (416) |
Ask (Ask size) | - (24,150) |
Open | 11.90 EUR |
High | 11.90 EUR |
Low | 11.70 EUR |
Close (prev. day) | 11.85 EUR |
VWAP | 11.762277 EUR |
Volume (pcs) | 5,657 |
Trading volume | 66,539.00 |
Number of trades | 52 |
Last size | 97 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/03 |
![]() |
Global Strategy 3Q 2024 |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/04/26 |
![]() |
Global Equity Ratings |
![]() |
2024/03/26 |
![]() |
Global Strategy 2Q 2024 |
![]() |
2024/04/26 17:37:36 | |
---|---|
Price | |
11.70 EUR | |
Difference | -1.27% (-0.15) |
ISIN | BE0974363955 |
Symbol | 52U |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 202 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - (416) |
Ask (Ask size) | - (24,150) |
Open | 11.90 EUR |
High | 11.90 EUR |
Low | 11.70 EUR |
Close (prev. day) | 11.85 EUR |
VWAP | 11.762277 EUR |
Volume (pcs) | 5,657 |
Trading volume | 66,539.00 |
Number of trades | 52 |
Last size | 97 |
6m | 1Y | 3Y | |
Perf (%) | -5.65% | -8.95% | -9.30% |
Perf (abs.) | -0.70 | -1.15 | -1.20 |
Beta | -0.12 | 0.13 | 0.15 |
Volatility | 35.39 | 33.36 | 33.04 |
Ø price 5 days | Ø volume 5 days (pcs.) | 11.83 EUR (6,279) |
Ø price 30 days | Ø volume 30 days (pcs.) | 11.84 EUR (14,992) |
Ø price 100 days | Ø volume 100 days (pcs.) | 12.32 EUR (11,731) |
Ø price 250 days | Ø volume 250 days (pcs.) | 12.01 EUR (7,711) |
YTD High | date | 13.30 EUR (2024/01/03) |
YTD Low | date | 11.00 EUR (2024/03/22) |
52 Weeks High | date | 14.10 EUR (2023/10/18) |
52 Weeks Low | date | 10.60 EUR (2023/12/20) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2024/04/29 | 08:08 | 11.55 EUR | 0.00 | 3 |
London Stock Exchange | - | - | - | 0.00 | - |
Frankfurt | 2024/04/29 | 08:22 | 11.40 EUR | 0.00 | 2 |
Euronext Brussels | 2024/04/26 | 17:37 | 11.70 EUR | 0.07 | 52 |
Duesseldorf | 2024/04/29 | 08:12 | 11.50 EUR | 0.00 | 1 |
HYLORIS PHARMACEUTICALS SA |
- - |
Boulevard Patience et Beaujonc N°3/1 - 4000 Liege |
Telefon: +32-4-346-02-07 |
Fax: + |
E-mail: contact@hyloris.com |
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation; and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium. |
Stijn van Rompay | Chairman of Managing Board |
Dietmar Aichhorn | Member of Executive Committee |
Jean-Luc Vandebroek | Member of Executive Committee |
Koenraad van der Elst | Member of Executive Committee |
Thomas Jacobsen | Member of Executive Committee |
Stefan Yee | Chairman of Supervisory Board |
Carolyn Myers | Member of Supervisory Board |
Chris Buyse | Member of Supervisory Board |
James Gale | Member of Supervisory Board |
Leon van Rompay | Member of Supervisory Board |
Marc Foidart | Member of Supervisory Board |
Thomas Jacobsen | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer